Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Antigen 7 (Ag7), often referred to as Low molecular weight antigen 7, is a small immunodominant protein identified primarily in Leishmania species. It plays a significant role in the host's immune recognition during infection, serving as a target for both humoral and cellular immune responses. Due to its high conservation across various Leishmania strains and its ability to elicit a strong Th1-type immune response, it has been extensively studied as a candidate for subunit vaccines and as a diagnostic marker for visceral and cutaneous leishmaniasis. In a therapeutic context, Ag7 is not a target for traditional small-molecule drugs but is a focal point for immunotherapeutic strategies and vaccine design aimed at preventing or controlling parasitic load. Its small size and stable structure make it an ideal candidate for recombinant expression and use in standardized diagnostic kits to detect anti-Leishmania antibodies in clinical samples.
Research-stage target for vaccine development and diagnostic assays; primarily functions as an immunodominant epitope for T-cell and B-cell recognition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Antigen 7 (Ag7).